Global Hematopoietic Progenitor Cells Transplantation 麻豆原创 Research Report 2023

Publication ID:

PB504246914

Publication Date:

May 11, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Highlights
The global Hematopoietic Progenitor Cells Transplantation market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Hematopoietic Progenitor Cells Transplantation is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Hematopoietic Progenitor Cells Transplantation is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Hematopoietic Progenitor Cells Transplantation in Leukemia is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Hematopoietic Progenitor Cells Transplantation include CBR Systems, China Cord Blood Corporation, ViaCord, Thermo Fisher Scientific, STEMCELL Technologies, Vcanbio, Merck Millipore, Lonza Group and CellGenix Technologie Transfer, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Hematopoietic Progenitor Cells Transplantation, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hematopoietic Progenitor Cells Transplantation.
The Hematopoietic Progenitor Cells Transplantation market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Hematopoietic Progenitor Cells Transplantation market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hematopoietic Progenitor Cells Transplantation companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
CBR Systems
China Cord Blood Corporation
ViaCord
Thermo Fisher Scientific
STEMCELL Technologies
Vcanbio
Merck Millipore
Lonza Group
CellGenix Technologie Transfer
ThermoGenesis
Segment by Type
Hematopoietic Progenitor Cell Storage
Hematopoietic Progenitor Cells Consumables
Segment by Application
Leukemia
Lymphoproliferative Disorders
Solid Tumors
Non-Malignant Disorders
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hematopoietic Progenitor Cells Transplantation companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Hematopoietic Progenitor Cells Transplantation 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Hematopoietic Progenitor Cell Storage
1.2.3 Hematopoietic Progenitor Cells Consumables
1.3 麻豆原创 by Application
1.3.1 Global Hematopoietic Progenitor Cells Transplantation 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Leukemia
1.3.3 Lymphoproliferative Disorders
1.3.4 Solid Tumors
1.3.5 Non-Malignant Disorders
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hematopoietic Progenitor Cells Transplantation 麻豆原创 Perspective (2018-2029)
2.2 Hematopoietic Progenitor Cells Transplantation Growth Trends by Region
2.2.1 Global Hematopoietic Progenitor Cells Transplantation 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Hematopoietic Progenitor Cells Transplantation Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Hematopoietic Progenitor Cells Transplantation Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Hematopoietic Progenitor Cells Transplantation 麻豆原创 Dynamics
2.3.1 Hematopoietic Progenitor Cells Transplantation Industry Trends
2.3.2 Hematopoietic Progenitor Cells Transplantation 麻豆原创 Drivers
2.3.3 Hematopoietic Progenitor Cells Transplantation 麻豆原创 Challenges
2.3.4 Hematopoietic Progenitor Cells Transplantation 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hematopoietic Progenitor Cells Transplantation Players by Revenue
3.1.1 Global Top Hematopoietic Progenitor Cells Transplantation Players by Revenue (2018-2023)
3.1.2 Global Hematopoietic Progenitor Cells Transplantation Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Hematopoietic Progenitor Cells Transplantation 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hematopoietic Progenitor Cells Transplantation Revenue
3.4 Global Hematopoietic Progenitor Cells Transplantation 麻豆原创 Concentration Ratio
3.4.1 Global Hematopoietic Progenitor Cells Transplantation 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hematopoietic Progenitor Cells Transplantation Revenue in 2022
3.5 Hematopoietic Progenitor Cells Transplantation Key Players Head office and Area Served
3.6 Key Players Hematopoietic Progenitor Cells Transplantation Product Solution and Service
3.7 Date of Enter into Hematopoietic Progenitor Cells Transplantation 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Hematopoietic Progenitor Cells Transplantation Breakdown Data by Type
4.1 Global Hematopoietic Progenitor Cells Transplantation Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Hematopoietic Progenitor Cells Transplantation Forecasted 麻豆原创 Size by Type (2024-2029)
5 Hematopoietic Progenitor Cells Transplantation Breakdown Data by Application
5.1 Global Hematopoietic Progenitor Cells Transplantation Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Hematopoietic Progenitor Cells Transplantation Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Hematopoietic Progenitor Cells Transplantation 麻豆原创 Size (2018-2029)
6.2 North America Hematopoietic Progenitor Cells Transplantation 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Hematopoietic Progenitor Cells Transplantation 麻豆原创 Size by Country (2018-2023)
6.4 North America Hematopoietic Progenitor Cells Transplantation 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hematopoietic Progenitor Cells Transplantation 麻豆原创 Size (2018-2029)
7.2 Europe Hematopoietic Progenitor Cells Transplantation 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Hematopoietic Progenitor Cells Transplantation 麻豆原创 Size by Country (2018-2023)
7.4 Europe Hematopoietic Progenitor Cells Transplantation 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hematopoietic Progenitor Cells Transplantation 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Hematopoietic Progenitor Cells Transplantation 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Hematopoietic Progenitor Cells Transplantation 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Hematopoietic Progenitor Cells Transplantation 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hematopoietic Progenitor Cells Transplantation 麻豆原创 Size (2018-2029)
9.2 Latin America Hematopoietic Progenitor Cells Transplantation 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Hematopoietic Progenitor Cells Transplantation 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Hematopoietic Progenitor Cells Transplantation 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hematopoietic Progenitor Cells Transplantation 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Hematopoietic Progenitor Cells Transplantation 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Hematopoietic Progenitor Cells Transplantation 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Hematopoietic Progenitor Cells Transplantation 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 CBR Systems
11.1.1 CBR Systems Company Detail
11.1.2 CBR Systems Business Overview
11.1.3 CBR Systems Hematopoietic Progenitor Cells Transplantation Introduction
11.1.4 CBR Systems Revenue in Hematopoietic Progenitor Cells Transplantation Business (2018-2023)
11.1.5 CBR Systems Recent Development
11.2 China Cord Blood Corporation
11.2.1 China Cord Blood Corporation Company Detail
11.2.2 China Cord Blood Corporation Business Overview
11.2.3 China Cord Blood Corporation Hematopoietic Progenitor Cells Transplantation Introduction
11.2.4 China Cord Blood Corporation Revenue in Hematopoietic Progenitor Cells Transplantation Business (2018-2023)
11.2.5 China Cord Blood Corporation Recent Development
11.3 ViaCord
11.3.1 ViaCord Company Detail
11.3.2 ViaCord Business Overview
11.3.3 ViaCord Hematopoietic Progenitor Cells Transplantation Introduction
11.3.4 ViaCord Revenue in Hematopoietic Progenitor Cells Transplantation Business (2018-2023)
11.3.5 ViaCord Recent Development
11.4 Thermo Fisher Scientific
11.4.1 Thermo Fisher Scientific Company Detail
11.4.2 Thermo Fisher Scientific Business Overview
11.4.3 Thermo Fisher Scientific Hematopoietic Progenitor Cells Transplantation Introduction
11.4.4 Thermo Fisher Scientific Revenue in Hematopoietic Progenitor Cells Transplantation Business (2018-2023)
11.4.5 Thermo Fisher Scientific Recent Development
11.5 STEMCELL Technologies
11.5.1 STEMCELL Technologies Company Detail
11.5.2 STEMCELL Technologies Business Overview
11.5.3 STEMCELL Technologies Hematopoietic Progenitor Cells Transplantation Introduction
11.5.4 STEMCELL Technologies Revenue in Hematopoietic Progenitor Cells Transplantation Business (2018-2023)
11.5.5 STEMCELL Technologies Recent Development
11.6 Vcanbio
11.6.1 Vcanbio Company Detail
11.6.2 Vcanbio Business Overview
11.6.3 Vcanbio Hematopoietic Progenitor Cells Transplantation Introduction
11.6.4 Vcanbio Revenue in Hematopoietic Progenitor Cells Transplantation Business (2018-2023)
11.6.5 Vcanbio Recent Development
11.7 Merck Millipore
11.7.1 Merck Millipore Company Detail
11.7.2 Merck Millipore Business Overview
11.7.3 Merck Millipore Hematopoietic Progenitor Cells Transplantation Introduction
11.7.4 Merck Millipore Revenue in Hematopoietic Progenitor Cells Transplantation Business (2018-2023)
11.7.5 Merck Millipore Recent Development
11.8 Lonza Group
11.8.1 Lonza Group Company Detail
11.8.2 Lonza Group Business Overview
11.8.3 Lonza Group Hematopoietic Progenitor Cells Transplantation Introduction
11.8.4 Lonza Group Revenue in Hematopoietic Progenitor Cells Transplantation Business (2018-2023)
11.8.5 Lonza Group Recent Development
11.9 CellGenix Technologie Transfer
11.9.1 CellGenix Technologie Transfer Company Detail
11.9.2 CellGenix Technologie Transfer Business Overview
11.9.3 CellGenix Technologie Transfer Hematopoietic Progenitor Cells Transplantation Introduction
11.9.4 CellGenix Technologie Transfer Revenue in Hematopoietic Progenitor Cells Transplantation Business (2018-2023)
11.9.5 CellGenix Technologie Transfer Recent Development
11.10 ThermoGenesis
11.10.1 ThermoGenesis Company Detail
11.10.2 ThermoGenesis Business Overview
11.10.3 ThermoGenesis Hematopoietic Progenitor Cells Transplantation Introduction
11.10.4 ThermoGenesis Revenue in Hematopoietic Progenitor Cells Transplantation Business (2018-2023)
11.10.5 ThermoGenesis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

CBR Systems
China Cord Blood Corporation
ViaCord
Thermo Fisher Scientific
STEMCELL Technologies
Vcanbio
Merck Millipore
Lonza Group
CellGenix Technologie Transfer
ThermoGenesis

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.